NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free CDNA Stock Alerts $10.59 +0.07 (+0.67%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.28▼$11.1050-Day Range$7.96▼$12.0852-Week Range$4.80▼$12.93Volume696,817 shsAverage Volume1.04 million shsMarket Capitalization$548.35 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3.9% Upside$11.00 Price TargetShort InterestBearish8.82% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.38Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 starsMedical Sector749th out of 938 stocksMedical Laboratories Industry17th out of 20 stocks 1.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, CareDx has a forecasted upside of 3.9% from its current price of $10.59.Amount of Analyst CoverageCareDx has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.82% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in CareDx has recently increased by 15.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 3.0 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CareDx this week, compared to 3 articles on an average week.Search Interest6 people have searched for CDNA on MarketBeat in the last 30 days. MarketBeat Follows2 people have added CareDx to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.59) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Share Price Crosses Above 50-Day Moving Average of $9.64March 26, 2024 | msn.comReplimune Group announces CEO transitionMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 16, 2024 | finance.yahoo.comCDNA Apr 2024 2.500 callMarch 16, 2024 | finance.yahoo.comCDNA Apr 2024 10.000 putMarch 14, 2024 | msn.comUroGen Pharma reports mixed Q4 results; initiates FY24 outlookMarch 11, 2024 | businesswire.comCareDx Appoints Bryan Riggsbee to Its Board of DirectorsMarch 6, 2024 | markets.businessinsider.comCareDx Hold Rating: Balancing Modest Growth Prospects with Operational UncertaintiesMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 4, 2024 | finance.yahoo.comCDNA Mar 2024 17.500 callMarch 1, 2024 | finance.yahoo.comCareDx Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | finance.yahoo.comCareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | msn.comCareDx Non-GAAP EPS of -$0.17 beats by $0.10, revenue of $65.6M beats by $1.54MFebruary 28, 2024 | finance.yahoo.comCareDx Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.comCareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023February 27, 2024 | finance.yahoo.comCareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors ConferenceFebruary 27, 2024 | benzinga.comEarnings Outlook For CareDxFebruary 27, 2024 | businesswire.comCareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors ConferenceFebruary 22, 2024 | benzinga.comCareDx Stock (NASDAQ:CDNA), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comCareDx to Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | businesswire.comCareDx to Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comCareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem MeetingsFebruary 21, 2024 | businesswire.comCareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem MeetingsFebruary 17, 2024 | finance.yahoo.comCDNA Mar 2024 12.500 callFebruary 17, 2024 | finance.yahoo.comCDNA Mar 2024 7.500 putJanuary 30, 2024 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on CareDx (CDNA)January 29, 2024 | markets.businessinsider.comCareDx Announces Mixed Jury Verdict In Patent Litigation Against NateraSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees635Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$12.00 Low Stock Price Target$10.00 Potential Upside/Downside+3.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-67.88% Pretax Margin-67.83% Return on Equity-51.40% Return on Assets-37.85% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.77 Sales & Book Value Annual Sales$280.32 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book2.19Miscellaneous Outstanding Shares51,780,000Free Float49,604,000Market Cap$548.35 million OptionableOptionable Beta1.42 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMs. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerMr. Ian CooneyVice President of Investor RelationsJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsCelcuityNASDAQ:CELCCastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTSera PrognosticsNASDAQ:SERAHH&L AcquisitionNYSE:HHLAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 18,909 shares on 3/11/2024Ownership: 7.956%Wellington Management Group LLPBought 83,139 shares on 3/5/2024Ownership: 0.161%Bullseye Asset Management LLCBought 5,000 shares on 2/17/2024Ownership: 0.323%Price T Rowe Associates Inc. MDSold 15,937 shares on 2/16/2024Ownership: 0.050%GSA Capital Partners LLPSold 47,722 shares on 2/16/2024Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions Should I buy or sell CareDx stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDNA shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price target for 2024? 4 analysts have issued 1-year target prices for CareDx's stock. Their CDNA share price targets range from $10.00 to $12.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2024? CareDx's stock was trading at $12.00 at the start of the year. Since then, CDNA stock has decreased by 11.8% and is now trading at $10.59. View the best growth stocks for 2024 here. Are investors shorting CareDx? CareDx saw a increase in short interest in March. As of March 15th, there was short interest totaling 4,360,000 shares, an increase of 16.0% from the February 29th total of 3,760,000 shares. Based on an average daily volume of 971,200 shares, the days-to-cover ratio is currently 4.5 days. Currently, 8.8% of the company's shares are sold short. View CareDx's Short Interest. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $1.97. The business had revenue of $65.57 million for the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative trailing twelve-month return on equity of 51.40% and a negative net margin of 67.88%. The firm's revenue was down 20.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.34) earnings per share. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has CareDx issued on next quarter's earnings? CareDx updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). Who are CareDx's major shareholders? CareDx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (13.30%), Vanguard Group Inc. (7.61%), Vanguard Group Inc. (7.96%), Bellevue Group AG (7.31%), Sumitomo Mitsui Trust Holdings Inc. (5.31%) and Nikko Asset Management Americas Inc. (5.31%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDNA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.